Core Viewpoint - A class action lawsuit has been filed against Charter Communications, Inc. for allegedly misleading investors about its business prospects, particularly regarding the impact of the Affordable Connectivity Program's end on customer declines and revenue [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Charter failed to disclose the material impact of the Affordable Connectivity Program (ACP) ending, which affected Internet customer declines and revenue [2]. - It is alleged that Charter's operational strategies were not sufficient to mitigate the negative effects of the ACP ending, leading to greater risks to business plans and earnings growth than reported [2]. - The company reportedly provided overly optimistic statements about its operational execution and long-term EBITDA growth without a reasonable basis [2]. Group 2: Financial Performance - Charter reported an EBITDA of $5.7 billion for Q2 2025, indicating a year-over-year growth of 0.5%. However, this growth was attributed to a one-time benefit of $45 million in "other revenue" [3]. - Excluding this one-time benefit, EBITDA would have missed consensus estimates by 2.4% and shown a decline of 0.3% year-over-year [3]. - Following the financial results announcement, Charter's stock price dropped by $70.25, or over 18%, closing at $309.75 per share on July 25, 2025 [3].

Core Viewpoint - A class action has been filed against Unicycive Therapeutics, Inc. for allegedly misleading investors regarding the readiness of its drug application and compliance with FDA manufacturing requirements [1][2]. Group 1: Allegations and Legal Action - Robbins LLP is investigating allegations that Unicycive Therapeutics misled investors about the prospects of its New Drug Application (NDA) for oxylanthanum carbonate (OLC) [2]. - The complaint claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [2]. - Shareholders are encouraged to participate in the class action and can contact Robbins LLP before the October 14, 2025 deadline to serve as lead plaintiff [4]. Group 2: Stock Performance and FDA Actions - On June 10, 2025, Unicycive announced that the FDA identified deficiencies in cGMP compliance at a third-party manufacturing vendor, leading to a stock price drop of over 40% [3]. - Following the FDA's issuance of a Complete Response Letter for the OLC NDA on June 30, 2025, Unicycive's stock fell nearly 30%, closing at $4.77 per share [3].

Core Viewpoint - Robbins LLP has filed a class action on behalf of investors who acquired Fiserv, Inc. common stock during a specified period, alleging that the company misled investors regarding the growth prospects of its Clover platform [1][2]. Allegations - Fiserv allegedly forced Payeezy merchants to migrate to its Clover platform due to cost issues and problems with Payeezy, which temporarily boosted Clover's revenue and GPV growth, concealing a slowdown in new merchant business [2]. - Following the forced conversions, many former Payeezy merchants switched to competing solutions due to Clover's high pricing and inadequate customer service, leading to a significant slowdown in Clover's GPV growth and unsustainable revenue growth [2]. - The positive statements made by Fiserv regarding Clover's growth strategies and business prospects during the class period were claimed to be materially false and misleading [2]. Impact on Stock - The truth regarding these issues was revealed through a series of disclosures, resulting in a decline in Fiserv, Inc.'s stock and harming investors [3]. Next Steps for Shareholders - Shareholders interested in serving as lead plaintiffs must file their motions by September 22, 2025, while those who choose not to participate can remain as absent class members [4]. Company Background - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002, operating on a contingency fee basis where shareholders pay no fees or expenses [5].

Group 1 - A class action has been filed against Centene Corporation on behalf of investors who acquired its securities between December 12, 2024, and June 30, 2025 [1] - Allegations state that Centene misled investors about its business prospects, creating a false impression of reliable revenue outlook and growth while actual enrollment rates and morbidity were lower than expected [2] - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that market growth across 22 states was lower than anticipated, leading to a reduction in guidance to approximately $1.8 billion and an adjusted diluted EPS of $2.75 [3] Group 2 - Following the announcement on July 1, 2025, Centene's stock price dropped from $56.65 to $44.78 per share, a decline of over 40% [3] - Shareholders are encouraged to participate in the class action, with options to serve as lead plaintiff or remain an absent class member [4] - Robbins LLP has been dedicated to shareholder rights litigation since 2002, focusing on helping shareholders recover losses and improve corporate governance [5]

Core Viewpoint - A class action has been filed against CTO Realty Growth, Inc. for allegedly misleading investors about its financial health and sustainability of dividends during the specified period [1][2]. Allegations - The complaint states that CTO Realty Growth, Inc. did not disclose that its dividends were less sustainable than claimed, used deceptive practices to inflate its Adjusted Funds from Operations (AFFO), and overstated its business and financial prospects [2]. - Wolfpack Research's report accused CTO of not generating sufficient cash to cover its recurring capital expenditures and dividends since its conversion to a REIT in 2021, relying on a 70% increase in shares outstanding to cover a $38 million dividend shortfall from 2021 to 2024, and employing a manipulative definition of AFFO [3]. Financial Condition - The report highlighted that CTO had only $8.4 million in cash while facing quarterly dividends of $14 million and average recurring capital expenditures of $5.7 million, along with an additional $12 million in planned capital expenditures [3].

Core Viewpoint - A class action lawsuit has been filed against CTO Realty Growth, Inc. for allegedly misleading investors about its financial health and sustainability of dividends during the specified period [1][2]. Allegations - The lawsuit claims that CTO Realty Growth misrepresented the sustainability of its dividends, which were less stable than communicated to investors [2]. - It is alleged that the company employed deceptive practices to inflate its Adjusted Funds from Operations (AFFO) and overstated the profitability of its Ashford Lane property [2]. - The complaint highlights that CTO's business and financial prospects were overstated, leading to investor misinformation [2]. Financial Concerns - A report by Wolfpack Research accused CTO of failing to generate sufficient cash to cover its recurring capital expenditures and dividends since its conversion to a REIT in 2021 [3]. - The report noted that CTO increased its shares outstanding by 70% since December 2022 to cover a $38 million dividend shortfall from 2021 to 2024 [3]. - CTO reportedly has only $8.4 million in cash while facing quarterly dividends of $14 million and average recurring capital expenditures of $5.7 million per quarter, along with an additional $12 million in planned capital expenditures [3]. Stock Impact - Following the publication of the report, CTO's stock price fell by over 5% [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must submit their papers by October 7, 2025 [4]. - Shareholders can remain absent class members if they choose not to participate in the case [4]. Company Background - Robbins LLP is noted as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance [5].

Core Viewpoint - A class action lawsuit has been filed against Lineage, Inc. for allegedly misleading investors during its 2024 IPO, with claims that the company failed to disclose significant operational challenges and declining market conditions [1][2]. Group 1: Allegations Against Lineage, Inc. - The registration statement for the IPO filed on June 26, 2024, was claimed to be false and misleading, failing to disclose that Lineage was experiencing a decline in customer demand due to increased cold-storage supply and destocking of excess inventory from the COVID-19 pandemic [2]. - Lineage reportedly implemented unsustainable price increases prior to the IPO, which could not be maintained in the face of weakening demand [2]. - The company was unable to counteract adverse trends through operational efficiencies or competitive advantages, leading to stagnant or falling revenue, occupancy rates, and rent prices, contrary to the representations made in the registration statement [2]. Group 2: Stock Performance - Since the IPO, Lineage's stock price has dropped to approximately $40 per share, remaining significantly below the IPO price at the time of the complaint [3]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must submit their papers by September 30, 2025, although participation is not required to be eligible for recovery [4].

Group 1: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - The class period for Sarepta is from June 22, 2023, to June 24, 2025, with a lead plaintiff deadline of August 25, 2025 [2] - The lawsuit alleges that Sarepta made materially false and misleading statements regarding its gene therapy ELEVIDYS, which was intended to treat Duchenne muscular dystrophy, leading investors to believe it was safe and had a positive revenue outlook [2] - Significant safety risks associated with ELEVIDYS were not disclosed, including severe side effects that led to the halting of trials and regulatory scrutiny [2][3] - Following the announcement of a patient death related to ELEVIDYS, Sarepta's stock price fell by $27.81 (27.44%) to close at $73.54 on March 18, 2025 [3] - Subsequent disclosures of additional patient deaths and regulatory investigations resulted in further stock price declines, with a notable drop of $15.24 (42.12%) to close at $20.91 on June 15, 2025 [3] Group 2: Petco Health and Wellness Company, Inc. (NASDAQ:WOOF) - The class period for Petco is from January 14, 2021, to June 5, 2025, with a lead plaintiff deadline of August 29, 2025 [4] - The lawsuit claims that Petco made materially false and misleading statements about its business operations, particularly regarding the sustainability of pandemic-related growth and the viability of its premium pet food business model [4][5] - Defendants allegedly overstated Petco's ability to achieve sustainable, profitable growth, with a specific reference to a share price of $95.85 on May 21, 2025 [5]

Core Viewpoint - A class action lawsuit has been filed against Lockheed Martin Corporation, alleging that the company misled investors regarding its business prospects and internal controls [1][2]. Allegations - The complaint states that Lockheed Martin failed to disclose several critical issues, including: - Inefficient internal controls related to risk-adjusted contracts and profit booking rates [2] - Lack of effective procedures for comprehensive reviews of program requirements and risks [2] - Overstatement of its ability to meet contract commitments in terms of cost, quality, and schedule [2] - Likelihood of reporting significant losses as a result of these issues [2] Financial Impact - On July 22, 2025, Lockheed Martin disclosed an additional $1.6 billion in pre-tax losses on classified programs, which included: - $950 million in losses from the Aeronautics Classified program - $570 million in losses from the Canadian Maritime Helicopter Program - $95 million charge related to the Turkish Utility Helicopter Program - Following this announcement, the company's share price dropped by $49.79, or over 10%, closing at $410.74 [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers by September 26, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses [5].

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug candidate ALTO-100 during its IPO and subsequent period [1][2]. Company Overview - Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company based in the U.S. with a product pipeline that includes ALTO-100, which was in a Phase 2b clinical trial for treating major depressive disorder (MDD) at the time of its IPO [1]. Allegations - The lawsuit claims that the Offering Documents related to the IPO were negligently prepared and that the company failed to disclose critical information about ALTO-100's effectiveness, overstating its clinical, regulatory, and commercial prospects [2]. - Specifically, it is alleged that ALTO-100 was less effective in treating MDD than represented, leading to an overestimation of Alto's business and financial prospects [2]. Stock Performance - Following the announcement on October 22, 2024, that ALTO-100 did not meet its primary endpoint in the Phase 2b trial, Alto's stock price plummeted by $10.17 per share, a decrease of 69.99%, closing at $4.36 per share on October 23, 2024 [3]. Legal Proceedings - Shareholders interested in participating in the class action have until September 19, 2025, to seek lead plaintiff status, which allows them to represent other class members in the litigation [4].